Oscar Health Touts Q1 Strength at Goldman Conference, But DeepValue Report Warns of Unsustainable Profitability and Risk Adjustment Drag

What happened

Oscar Health presented at Goldman Sachs' healthcare conference, likely emphasizing its record membership and Q1 earnings beat. However, the DeepValue master report flags that Q1's 70.5% MLR was artificially low due to $68M favorable reserve development, far below the FY2026 guidance range of 82.4%-83.4%. Meanwhile, the net risk-adjustment payable ballooned to $3.97B, with management guiding the accrual at ~24% of direct premiums in Q1 versus ~20% expected for the full year. The report also notes that the expiration of enhanced APTCs has already reduced Marketplace participation and Oscar's membership since open enrollment, threatening scale-driven SG&A leverage. With the stock at $20.9, the market is pricing in durable profitability that the filings directly contradict, making the conference presentation a likely effort to sustain bullish sentiment ahead of inevitable normalization.

Implication

Oscar's underlying business faces structural headwinds from risk-adjustment drag, subsidy expiration, and medical cost normalization. Unless Q2-Q3 evidence shows RA accrual trending ≤21% and net payable stabilizing near $4B, the equity shifts from an earnings compounder to a capital-at-risk story. Long-term investors should demand clear evidence of risk score improvement before building positions.

Thesis delta

The bull case relies on Q1's profitability being repeatable, but the deep report demonstrates it was driven by one-off reserve development and a seasonally low MLR. The upcoming quarters will test whether risk-adjustment drag is structural or normalizing, with a likely negative outcome that shifts the narrative from operating leverage to regulatory transfer risk.